Alternate-day treatment with S-1 in patients with gastric cancer: A retrospective study of strategies for reducing toxicity

International Journal of Clinical Oncology

Volumn 15, Issue 2, 2010, Pages 166-171

  Sakuma, Kazuya ^a   Hosoya, Yoshinori ^a   Arai, Wataru ^a   Haruta, Hidenori ^a   Ui, Takashi ^a   Kurashina, Kentaro ^a   Saito, Shin ^a   Hirashima, Yuki ^a   Yokoyama, Taku ^a   Zuiki, Toru ^a   Hyodo, Mananobu ^a   Nagai, Hideo ^b   Yasuda, Yoshikazu ^a   Shirasaka, Tetsuhiko ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

Adverse events; Alternate day treatment; Gastric cancer; S 1; TS 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LONG TERM CARE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PIGMENT DISORDER; POOR GENERAL CONDITION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; SIDE EFFECT; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; GASTRECTOMY; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODE EXCISION; MALE; MIDDLE AGED; OXONIC ACID; PALLIATIVE CARE; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950961920     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0036-y     Document Type: Article

References (23)

1. Boku N (2008) Chemotherapy for metastatic gastric cancer in Japan. Int J Clin Oncol 13:483-487
2. T Yamanaka S Matsumoto S Teramukai, et al. 2008 Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3, 758 patients Cancer Chemother Pharmacol 61 335 343 10.1007/s00280-007-0595-4 1:CAS:528:DC%2BD2sXhtlWrs7zM 17922276 (Pubitemid 350160333)
3. S Sakuramoto M Sasako T Yamaguchi, et al. 2007 Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 1810 1820 10.1056/NEJMoa072252 1:CAS:528:DC%2BD2sXht1Kit7bI 17978289 (Pubitemid 350044801)
4. W Koizumi H Narahara T Hara, et al. 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221 10.1016/S1470-2045(08)70035-4 1:CAS:528:DC%2BD1cXivVaqtb4%3D 18282805
5. Y Sakata A Ohtsu N Horikoshi, et al. 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 in advanced gastric cancer patients Eur J Cancer 34 1715 1720 10.1016/S0959-8049(98)00211-1 1:CAS:528: DyaK1cXntlShurw%3D 9893658 (Pubitemid 28474225)
6. W Koizumi M Kurihara S Nakano, et al. 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 191 197 10.1159/000012099 1:CAS:528:DC%2BD3cXjvVeitr4%3D 10765119 (Pubitemid 30189900)
7. W Arai Y Hosoya M Hyodo, et al. 2002 Every-other-day TS-1 administration for recurrent or non-curative advanced gastric carcinoma (in Japanese) Gan To Kagaku Ryoho 29 1651 1655 12355955
8. W Arai Y Hosoya T Yokoyama, et al. 2004 A case of type 4 gastric cancer with peritoneal dissemination successfully treated over 2 years by alternate-day administration of TS-1 (in Japanese) Gan To Kagaku Ryoho 31 237 240 14997759
9. W Arai Y Hosoya M Hyodo, et al. 2004 Alternate-day oral therapy with TS-1 for advanced gastric cancer Int J Clin Oncol 9 143 148 1:CAS:528: DC%2BD2cXltVKntb0%3D 15221596
10. W Arai Y Hosoya H Haruta, et al. 2008 Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo Int J Clin Oncol 13 515 520 10.1007/s10147-008-0780-4 1:CAS:528:DC%2BD1cXhsFSrurjI 19093179
11. Boku N, Yamamoto S, Shirao K et al (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Annual Meeting of ASCO (abstract LBA4513)
12. K Nakashima S Hironaka N Boku, et al. 2008 Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution Jpn J Clin Oncol 38 810 815 10.1093/jjco/hyn109 18988666
13. Japanese Gastric Cancer Association 1998 Japanese classification of gastric carcinoma-2nd English edition Gastric Cancer 1 10 24 10.1007/PL00011681 11957040
14. F Nagashima A Ohtsu S Yoshida, et al. 2005 Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer Gastric Cancer 8 6 11 10.1007/s10120-004-0306-3 15747168 (Pubitemid 40394918)
15. T Shirasaka 2009 Development history and concept of an oral anticancer agent S-1: its clinical usefulness and future vistas Jpn J Clin Oncol 39 2 15 10.1093/jjco/hyn127 19052037
16. Cronkite EP, Bond VP, Fliedner YM et al (1960) The use of tritiated thymidine in the study of haemopoietic cell proliferation. In: Wolsteinholme GEW, O'Connor M (eds) Ciba foundation symposium on haemopoiesis. Little Brown & Co, Boston, pp 56, 70-98
17. M Lipkin P Sherlock B Bell 1963 Cell proliferation kinetics in the gastrointestinal tract of man II cell renewal stomach, ileum, colon, and rectum Gastroenterology 45 721 729 1:STN:280:DyaF2c%2FptFyquw%3D%3D 14134007
18. B Clarkson K Ota T Ohkita, et al. 1965 Kinetics of proliferation of cancer cell in neoplastic effusions in man Cancer 18 1189 1213 10.1002/1097-0142(196510)18:10<1189::AID-CNCR2820181002>3.0.CO;2-8 1:STN:280:DyaF28%2FhslSntQ%3D%3D 5890960
19. T Shiraska S Yamamitsu A Tsuji, et al. 2000 Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan Invest New Drugs 18 315 329 10.1023/A:1006476730671
20. N Boku 2008 Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group. Chemotherapy for metastatic disease: review from JCOG trials Int J Clin Oncol 13 196 200 10.1007/s10147-008-0784-0 1:CAS:528: DC%2BD1cXntFKhsrc%3D 18553227 (Pubitemid 351876992)
21. Imamura H, IIishi H, Tsuburaya A et al (2008) Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). ASCO gastrointestinal symposium (abstract 5)
22. K Fujitani HK Yang Y Kurokawa, et al. 2008 Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01 Jpn J Clin Oncol 38 504 506 10.1093/jjco/hyn058 18617536
23. Sato A, Koizumi W, Akiya T et al (2009) Phase II study of S-1 as first-line treatment for elderly patients (pts) over 75 years with advanced gastric cancer (AGC). ASCO gastrointestinal symposium (abstract 82)